Date of Abstract presentation12th December 2023IndicationsMantle Cell Lymphoma (MCL)Abstract NumberLBA-2Abstract typeOral Ibrutinib, an oral BTK inhibitor, holds approval in numerous countries for ...
Date of Abstract presentation11th December 2023IndicationsRelapsed or Refractory (R/R) B-Cell MalignanciesAbstract Number4401Abstract typePoster The preliminary results from this ongoing clinical trial, unveiled at the ASH 2023 conference, demonstrated that, among the efficacy evaluable patients (n=28), BGB-1667...
Find More
Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1014Abstract typeOral TALVEY (talquetamab) is a bispecific T-cell engaging antibody designed to target the CD3 receptor found on T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D). The findings presente...
Find More
Micro Medical Solutions Announced Completion of Enrollment in Pivotal STAND Clinical Trial On December 6, 2023, Micro Medical Solutions (MMS) made an announcement on the completion of a pivotal clinical study enrollment in the United States. MMS microvascular intervention is intended to improve clinical outcomes...
Find More
Date of Abstract presentation12th December 2023IndicationsAcute LeukemiaAbstract NumberLBA-5Abstract typePoster According to the data presented at the ASH 2023 conference, as of the July 2023 data cutoff, the pivotal trial AUGMENT-101 included 94 patients with acute leukemia within the KMT2Ar cohorts. Among them...
Find More
Date of Abstract presentation12th December 2023IndicationsMultiple MyelomaAbstract NumberLBA1Abstract typeOral The PERSEUS study is being conducted in collaboration with the European Myeloma Network as a sponsor. PERSEUS is an ongoing, randomized, open-label, Phase III study comparing the efficacy and safety of ...
Find More
Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1063Abstract typeOral According to the findings presented at the ASH 2023, the CARTITUDE-4 trial included a cohort of 419 patients. As of the clinical cut-off, 99 patients in the CARVYKTI arm and 66 in the standard of care (...
Find More
Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1021Abstract typeOral CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s T cells with a transge...
Find More
Date of Abstract presentation10th December 2023IndicationsDiffuse Large B-cell lymphoma (DLBCL)Abstract Number436Abstract typeOral Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-c...
Find More
Date of Abstract presentation10th December 2023IndicationsFollicular LymphomaAbstract Number3026Abstract typeOral According to the data presented at the ASH 2023 conference, a cohort of 48 patients was analyzed for efficacy, revealing a 50% overall response rate (ORR) and a 14.6% complete response (CR) rate. Add...
Find More
There are about 200 different types of cancer, making it one of the most diverse types of indication.....
Find More
Progressive Supranuclear Palsy (PSP) is a rare progressive disorder resulting from damage that occur.....
Find More
Anorexia is the loss of the desire to eat, whereas cachexia results from the skeletal muscle mass in.....
Find More
Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of.....
Find More
Medical device manufacturing and development is a high-capital demanding endeavor and therefore the .....
Find More
Methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by bacteria that have become .....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
